Therefore, PD-1/PD-L1 inhibitors such as nivolumab and pembrolizumab are recommended as second-line treatment for advanced HCC according to the HCC official guidelines (51–53). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.